


About Ascelia Pharma

Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. Our strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. We currently have two drug candidates – Mangoral® and Oncoral – in clinical development.



MANGORAL® – Phase 3 liver contrast agent with no competition

Mangoral is a non-gadolinium oral contrast agent used for MRI-scans to improve visualisation of focal liver lesions (incl. liver metastases). Detecting liver metastases early is crucial for determining the right treatment method and thus the patient's chances of survival.


Mangoral targets patients with severely impaired kidney function who, due to the risk of serious, and potentially fatal, side effects cannot use the currently available contrast agents containing the heavy-metal gadolinium.

Mangoral has completed six Phase 1 and Phase 2 studies with strong clinical results and is currently in Phase 3. The ongoing pivotal Phase 3 study is a global multicentre study in up to 200 patients. First patient was enrolled in February 2020 and study results are expected in the second half of 2021.


The addressable market for Mangoral is estimated at \$350–500 million annually and Mangoral is expected to be the only product on the market for its patient segment. Mangoral has received Orphan Drug Designation from the US Food and Drug Administration (FDA).

Patient in the Phase 2 study

MRI without contrast agent (standard of care) – no metastases found



MRI with Mangoral Liver metastases clearly visible



ONCORAL – Phase 2 ready novel oral chemotherapy tablet

Oncoral is our novel oral chemotherapy tablet for the treatment of gastric cancer, which is also considered an orphan drug indication. Oncoral is taken in tablet form, giving patients the opportunity to receive part of their chemotherapy at home and at the same time enabling cost savings for the hospitals.

Oncoral completed Phase I studies with promising results and is now ready for Phase 2 development. The clinical development strategy for Oncoral is to obtain Phase 2 data and then enter into collaborations with a suitable partner for further development, market approval and commercialisation.

COMPANY FACTS

Founded	2000
Headquarter	Malmö, Sweden
Stock Exchange	NASDAQ Stockholm
Stock ticker	ACE
Drug candidates	Mangoral® and Oncoral
Key Executives	Peter Benson, Chairman Magnus Corfitzen, CEO Carl Bjartmar, CMO Kristian Borbos, CFO Julie Waras Brogren, CCO

MARKET DATA (May 2020)

Market Cap	SEK 502m	
Shares Outstanding	23.5m	
Top Shareholders	Sunstone Capital	19.1%
	CMC-SPV	12.5%
	Øresund Healthcare	8.6%
	Alto Invest	5.0%
	Handelsbanken Funds	4.5%
	Fjärde AP-fonden	4.2%

KEY FINANCIALS

SEK million	2019 (6M)	FY 18/19
EBIT	-38.8	-37.4
Net profit	-39.9	-37.1
Cash & Liquid assets	184.2	225.0
Equity	237.1	276.1
Operating Cash Flow	-36.9	-30.3

CALENDAR

May 26, 2020	ABG Life Science Summit
May 27, 2020	Redeye orphan drugs event
Aug 20, 2020	Q2 Financial Report
Nov 5, 2020	Q3 Financial Report

CONTACTS

Mikael Widell Head of IR mw@ascelia.com M: +46 709 298 269	Kristian Borbos CFO kb@ascelia.com M: +46 735 179 113
--	---